BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: García-Aranda M, Redondo M. Targeting Protein Kinases to Enhance the Response to anti-PD-1/PD-L1 Immunotherapy. Int J Mol Sci 2019;20:E2296. [PMID: 31075880 DOI: 10.3390/ijms20092296] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 6.7] [Reference Citation Analysis]
Number Citing Articles
1 Akbari H, Taghizadeh-Hesary F, Bahadori M. Mitochondria determine response to anti-programmed cell death protein-1 (anti-PD-1) immunotherapy: An evidence-based hypothesis. Mitochondrion 2022;62:151-8. [PMID: 34890822 DOI: 10.1016/j.mito.2021.12.001] [Reference Citation Analysis]
2 Bansal D, Reimers MA, Knoche EM, Pachynski RK. Immunotherapy and Immunotherapy Combinations in Metastatic Castration-Resistant Prostate Cancer. Cancers (Basel) 2021;13:334. [PMID: 33477569 DOI: 10.3390/cancers13020334] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
3 Li L, Wei JR, Dong J, Lin QG, Tang H, Jia YX, Tan W, Chen QY, Zeng TT, Xing S, Qin YR, Zhu YH, Li Y, Guan XY. Laminin γ2-mediating T cell exclusion attenuates response to anti-PD-1 therapy. Sci Adv 2021;7:eabc8346. [PMID: 33536206 DOI: 10.1126/sciadv.abc8346] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
4 Thangam R, Patel KD, Kang H, Paulmurugan R. Advances in Engineered Polymer Nanoparticle Tracking Platforms towards Cancer Immunotherapy-Current Status and Future Perspectives. Vaccines (Basel) 2021;9:935. [PMID: 34452059 DOI: 10.3390/vaccines9080935] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Haibe Y, El Husseini Z, El Sayed R, Shamseddine A. Resisting Resistance to Immune Checkpoint Therapy: A Systematic Review. Int J Mol Sci 2020;21:E6176. [PMID: 32867025 DOI: 10.3390/ijms21176176] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
6 Balibegloo M, Rezaei N. Development and clinical application of bispecific antibody in the treatment of colorectal cancer. Expert Rev Clin Immunol 2020;16:689-709. [PMID: 32536227 DOI: 10.1080/1744666X.2020.1783249] [Reference Citation Analysis]
7 Camorani S, Passariello M, Agnello L, Esposito S, Collina F, Cantile M, Di Bonito M, Ulasov IV, Fedele M, Zannetti A, De Lorenzo C, Cerchia L. Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer. J Exp Clin Cancer Res 2020;39:180. [PMID: 32892748 DOI: 10.1186/s13046-020-01694-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
8 Hartman ML, Rogut M, Mielczarek-Lewandowska A, Wozniak M, Czyz M. 17-Aminogeldanamycin Inhibits Constitutive Nuclear Factor-Kappa B (NF-κB) Activity in Patient-Derived Melanoma Cell Lines. Int J Mol Sci 2020;21:E3749. [PMID: 32466509 DOI: 10.3390/ijms21113749] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Hattinger CM, Patrizio MP, Magagnoli F, Luppi S, Serra M. An update on emerging drugs in osteosarcoma: towards tailored therapies? Expert Opin Emerg Drugs 2019;24:153-71. [PMID: 31401903 DOI: 10.1080/14728214.2019.1654455] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
10 Finelli C. Obesity and immunotherapy: the surprisingly positive association! Immunotherapy 2020;12:541-4. [PMID: 32345093 DOI: 10.2217/imt-2019-0143] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Mao C, Zeng X, Zhang C, Yang Y, Xiao X, Luan S, Zhang Y, Yuan Y. Mechanisms of Pharmaceutical Therapy and Drug Resistance in Esophageal Cancer. Front Cell Dev Biol 2021;9:612451. [PMID: 33644048 DOI: 10.3389/fcell.2021.612451] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 García-Aranda M, Redondo M. Immunotherapy: A Challenge of Breast Cancer Treatment. Cancers (Basel) 2019;11:E1822. [PMID: 31756919 DOI: 10.3390/cancers11121822] [Cited by in Crossref: 45] [Cited by in F6Publishing: 33] [Article Influence: 15.0] [Reference Citation Analysis]
13 Yu CC, Wortman JC, He TF, Solomon S, Zhang RZ, Rosario A, Wang R, Tu TY, Schmolze D, Yuan Y, Yost SE, Li X, Levine H, Atwal G, Lee PP. Physics approaches to the spatial distribution of immune cells in tumors. Rep Prog Phys 2021;84:022601. [PMID: 33232952 DOI: 10.1088/1361-6633/abcd7b] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
14 Zhang T, Zheng S, Liu Y, Li X, Wu J, Sun Y, Liu G. DNA damage response and PD-1/PD-L1 pathway in ovarian cancer. DNA Repair (Amst) 2021;102:103112. [PMID: 33838550 DOI: 10.1016/j.dnarep.2021.103112] [Reference Citation Analysis]
15 Pérez-Ruiz E, Melero I, Kopecka J, Sarmento-Ribeiro AB, García-Aranda M, De Las Rivas J. Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies. Drug Resist Updat 2020;53:100718. [PMID: 32736034 DOI: 10.1016/j.drup.2020.100718] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 11.0] [Reference Citation Analysis]
16 Baraibar I, Roman M, Rodríguez-Remírez M, López I, Vilalta A, Guruceaga E, Ecay M, Collantes M, Lozano T, Alignani D, Puyalto A, Oliver A, Ortiz-Espinosa S, Moreno H, Torregrosa M, Rolfo C, Caglevic C, García-Ros D, Villalba-Esparza M, De Andrea C, Vicent S, Pío R, Lasarte JJ, Calvo A, Ajona D, Gil-Bazo I. Id1 and PD-1 Combined Blockade Impairs Tumor Growth and Survival of KRAS-mutant Lung Cancer by Stimulating PD-L1 Expression and Tumor Infiltrating CD8+ T Cells. Cancers (Basel) 2020;12:E3169. [PMID: 33126649 DOI: 10.3390/cancers12113169] [Reference Citation Analysis]
17 Msaouel P, Genovese G, Gao J, Sen S, Tannir NM. TAM kinase inhibition and immune checkpoint blockade- a winning combination in cancer treatment? Expert Opin Ther Targets 2021;25:141-51. [PMID: 33356674 DOI: 10.1080/14728222.2021.1869212] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Emami N, Pakchin PS, Ferdousi R. Computational predictive approaches for interaction and structure of aptamers. J Theor Biol 2020;497:110268. [PMID: 32311376 DOI: 10.1016/j.jtbi.2020.110268] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
19 Nguyen HD, Liao YC, Ho YS, Chen LC, Chang HW, Cheng TC, Liu D, Lee WR, Shen SC, Wu CH, Tu SH. The α9 Nicotinic Acetylcholine Receptor Mediates Nicotine-Induced PD-L1 Expression and Regulates Melanoma Cell Proliferation and Migration. Cancers (Basel) 2019;11:E1991. [PMID: 31835799 DOI: 10.3390/cancers11121991] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]